

Serial No. (to be assigned)
28 September 2001
Page 3

REMARKS

The claims have been amended to delete multiple dependencies and to place them in order for examination. No new matter has been added by these amendments, and their entry is therefore requested.

RESPECTFULLY SUBMITTED,					
NAME AND REG. NUMBER	Jeffrey L. Ihnen, Registration No. 28,957				
SIGNATURE			DATE	28 SEPTEMBER 2001	
Address	ROTHWELL, FIGG, ERNST & MANBECK Suite 701-East, 555 13th Street, N.W.				
City	Washington	State	D.C.	Zip Code	20004
Country	U.S.A.	Telephone	202-783-6040	Fax	202-783-6031

Attachments: Marked-Up Copies of Amendments

Amended Claims - Changes made

4 (amended). A method for treating a person, diagnosed for having an increased risk for the development of atherosclerosis [according to claim 1 or 2] on the basis of a polymorphism in the signal peptide part of the human preproNPY, said polymorphism comprising the substitution of the position 7 leucine for proline in the signal peptide part of said preproNPY, for the prevention of developing atherosclerosis, comprising administering to said person an effective amount of an agent counteracting the influence of the mutated NPY gene.

7 (amended). A method for treating a person, diagnosed for having an increased risk for the development of atherosclerosis [according to claim 1 or 2] on the basis of a polymorphism in the signal peptide part of the human preproNPY, said polymorphism comprising the substitution of the position 7 leucine for proline in the signal peptide part of said preproNPY, for the prevention of developing atherosclerosis, comprising subjecting the person to specific gene therapy aimed to repair the mutated NPY sequence.

8 (amended). A method for treating a diabetic person, diagnosed for having an increased risk for the development of diabetic retinopathy [according to claim 3] on the basis of a polymorphism in the signal peptide part of the human preproNPY, said polymorphism comprising the substitution of the position 7 leucine for proline in the signal peptide part of said preproNPY, for the prevention of developing diabetic retinopathy, comprising administering to said person an effective amount of an agent counteracting the influence of the mutated NPY gene.

11 (amended). A method for treating a diabetic person, diagnosed for having an increased risk for the development of diabetic retinopathy [according to claim 3] on the basis of a polymorphism in the signal peptide part of the human preproNPY, said polymorphism comprising the substitution of the position 7 leucine for proline in the signal peptide part of said preproNPY, for the prevention of developing diabetic retinopathy, comprising subjecting the person to specific gene therapy aimed to repair the mutated NPY sequence.